Skip to main content

Raise Your Profile

Whether you are looking to attract a new business client, investment and partnering deal flow or talent, among other goals, One Nucleus offers a wide range of opportunities to raise your profile to our members and others in the Cambridge-London life sciences corridor, and wider local and international ecosystems.
Raise Your Profile
  • Discounts for Members

    Discounts for Members

    Members can take advantage of discounts on a wide range of products and services to maximise their return on the member subscription, often recovering multiples of the fees paid. Receive discounted rates on laboratory supplies, services, key industry events and more.
    Learn more
  • Connect with Our Network

    Connect with Our Network

    A key advantage to any company joining One Nucleus is the ability to connect to potential partners, investors, service providers, clients and their peers for knowledge-sharing. We do this through our varied range of informative networking events, which tend to be situated throughout Cambridge and London.
    Learn more
  • Build the Best Teams

    Build the Best Teams

    One Nucleus recognises that a company’s employees are its most valuable asset and the competition for talented and skilled employees has never been fiercer in the region’s life science sector. One Nucleus offers a range of services and engagement opportunities in this critical area to help support our members and maintain the reputation of the sector.
    Learn more

Events

Connecting and meeting with business partners, fellow innovators and key advisers is a vital part of everyone's endeavours since it enables knowledge exchange and onward contact for mutual and collective success. Complementing the wider One Nucleus support activities our portfolio of events is designed to meet the needs of our network in terms of content, format, timing, peer-to-peer engagements and modes of delivery.
  • Events
  • Events
  • Events
  • Events

Membership Overview

With Gold and Silver membership options, our 400 company members and their staff can benefit from a wide variety of savings, profiling opportunities, and more.
  • Membership

About One Nucleus

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. 
  • About

One Nucleus Creates a New Membership Category for Those Who Find Themselves Between Life Science Jobs

A Supportive Membership Offer While You Plan Your Next Step

Being made redundant, or finding yourself between roles for any reason, can be an unsettling time. It can also be an important moment to reconnect with your professional community, explore new opportunities, and invest in your next step.

Amphista Therapeutics Announces First Patient Dosed in AMX-883 Phase 1 Clinical Trial for Acute Myeloid Leukemia

  • AMX-883, Amphista’s first asset to enter the clinic, is a potent, selective, orally bioavailable DCAF16-mediated BRD9 degrader targeting acute myeloid leukemia (AML)
  • The first-in-human ‘BRAMLIE’ (BR(D9) AML Interventional Evaluation) trial will assess the safety, pharmacokinetics and preliminary efficacy of AMX-883 monotherapy in participants with AML and high-risk myelodysplastic syndrome (MDS)

Upcoming Opportunities to Learn & Develop from One Nucleus

With plenty happening across the life sciences sector, there’s always an opportunity to keep learning, build new skills and stay connected. We’ve brought together our latest learning opportunities, designed to support professionals at every career stage, alongside our popular in-house training, offering practical and relevant learning tailored to the needs of teams across academia and industry. 
________________________________________________

Upcoming Featured Opportunities

o2h Technology launches Tech Kickstarter 5.0 for seed and early-stage companies

The fifth edition of o2h Technology’s Tech Kickstarter Competition has been launched.

The contest has been helping seed and early-stage companies to accelerate their digital progress by transforming innovative ideas into market-ready products, using agentic AI, MVP development, web and mobile applications, and intelligent automation.

 

Senior Scientist in Cell Biology (Immunology Experience)

About the job

We have a vacancy for a Senior Scientist in cell biology with immunology experience. This is a great opportunity for a talented and passionate cell biologist to have an influential role in drug discovery projects at a well-respected integrated medicines research CRO on the outskirts of Cambridge, in Pampisford. This is a maternity cover opportunity for up to twelve months in the first instance which may develop into a permanent role in the future.

ELRIG and The Protein Society Announce Keynote Speakers for Protein Sciences in Drug Discovery 2026

  • Prof Dame Carol Robinson (University of Oxford), Dr Andrew Doré (Isomorphic Labs) and Prof Paula Booth (King’s College London) to lead event taking place from 10–11 November at GSK Stevenage
  • Programme to focus on AI, machine learning and data-driven approaches across protein design, characterisation and therapeutic development

High RNA Quality FFPE Tissue Blocks for Biomarker Discovery

Amsbio has expanded its range of high-quality FFPE tissues and controls specifically designed to support biomarker discovery, histopathology, translational research and assay development.

Although the tissue structure in FFPE samples is maintained for histological analysis, damage to the RNA incurred through the fixation, embedding, and storage processes advances with time and storage temperature. Sub-optimal tissue quality is one of the leading causes of misleading biomarker research.

Lipoprotein(a): Science, Clinical Development, and Strategic Opportunities for CROs

More  than 1.5 billion people worldwide carry elevated Lp(a) levels, a genetically determined cardiovascular risk factor for which no approved treatment exists. This combination of massive prevalence, robust causal evidence and an active therapeutic pipeline, makes Lp(a) research on of the most dynamic and operationally demanding areas for CROs in the coming decade.

Subscribe to